-$0.44 (-6.12%)
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Mark J. Litton |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ATHA |
| CUSIP | 04746L203 |
| CIK | 0001620463 |
| Web | https://www.athira.com |
| Phone | 425 620 8501 |
| Currency | USD |
| Employees | 26 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.38 |
| Quick Ratio | 10.38 |
| Cash Ratio | 4.93 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -12.15 |
| Price / Cash Flow | -0.64 |
| Price / Book | 0.73 |
Price Target and Rating
| Average Stock Price Forecast | $4.00 |
| High Stock Price Forecast | $33.00 |
| Low Stock Price Forecast | $3.00 |
| Forecast Upside/Downside | 68.75% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-24.7 |
| Trailing P/E Ratio | -0.28 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-105.61M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -381.01% |
| Return on Assets | -180.77% |
Financials Score
| AltmanZ Score | -9.26 |
| Piotroski Score | 2.00 |
| Working Capital | 62.54M |
| Total Assets | 71.59M |
| Ebit | -8.07M |
| Market Cap | 26.62M |
| Total Liabilities | 22.29M |
About Athira Pharma, Inc. (NASDAQ:ATHA) Stock
Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease. Additionally, ATH-1017 is in Phase 2 clinical trials for Parkinson's disease. The company also has several product candidates in earlier, preclinical stages of development, including ATH-1019 for conditions affecting the peripheral nervous system and ATH-1020 for neuropsychiatric ... disorders. Founded in 2011, the organization was known as M3 Biotechnology, Inc. until it rebranded to Athira Pharma, Inc. in April 2019.
ATHA Energy Announces Corporate Activities Update
2026-07-13 15:35:00
VANCOUVER, BC / ACCESS Newswire / July 13, 2026 / ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQX:SASKF) ("ATHA" or the "Company") announces the grant of an aggregate of 2,850,000 incentive stock options ("Options") and 2,200,000 restricted share units ("RSUs") to certain eligible participants, including certain directors and officers of the Company, under the Company's equity incentive plan (the "Plan"). One-third of the Options shall vest on the date of issuance thereof, one-third of the Options shall vest on the six-month anniversary of the date of issuance thereof, and the remaining one-third of the Options shall vest on the twelve-month anniversary of the date of issuance thereof.
2026-07-09 07:00:00
HIGHLIGHTS First eight diamond drillholes completed at the RIB North Discovery (Figure 1) - as part of the recently commenced 2026 Angilak Exploration Program - outline continuity of mineralization at the primary RIB North area, along strike from the maiden discovery hole, RIBN-DD-001, over 300 m. Additionally, the Company has discovered a secondary, east-west mineralized structure along the western limb of the Mineralized RIB Corridor ("MRC") approximately 1 km from the main RIB North Discovery Area (Figure 2); Drilling is focused on widely spaced step-outs, designed to outline the continuity of uranium mineralization at RIB North - the discovery remains open in all directions; Six of the eight drillholes intersected uranium mineralization, results are highlighted by: Drillhole RIBN-DD-003: Successfully targeted uranium mineralization ~120 m along strike to the Northwest from RIBN-DD-001, resulting in the intersection of 37.0 m of total composite uranium mineralization2 over fifteen zones from 541.7 m to 652.0 m (Figure 3).
2026-07-08 07:00:00
HIGHLIGHTS First regional test along the Lac 50 Deposit Corridor, as part of the recently commenced 2026 Angilak Exploration Program, results in major new discovery at Lac 50 Northwest, located ~4 km along strike from the Lac 50 Deposit area (Figure 1); The second hole at Lac 50 Northwest Discovery, L50W-DD-002, intersected 11.5 m of total composite uranium mineralization2 over five zones from 305.0 m to 479.9 m (Figure 2 & Table 1). The hole intersected 7.0 m of continuous mineralization (from 415.6 m to 422.6 m) averaging 7,974 counts per second (CPS1) including 1.6 m of high-grade mineralization2 with maximum radioactivity of 40,162 CPS1; Mineralization is basement-style, hosted within brecciated basalts, infilled with quartz-carbonite veining, displaying albite-hematite alteration halos and silicification overprinting.
OTC Markets Group Welcomes ATHA Energy Corp. to OTCQX
2026-06-30 07:00:00
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced ATHA Energy Corp. (TSX-V: SASK; OTCQX: SASKF and FRA: X5U), a uranium mineral exploration company, has qualified to trade on the OTCQX® Best Market. ATHA Energy Corp. upgraded to OTCQX from the OTCQB® Venture Market.
Athena Gold Provides Exploration Update from Excelsior Springs, Nevada
2026-06-16 07:00:00
White Rock, British Columbia--(Newsfile Corp. - June 16, 2026) - Athena Gold Corporation (CSE: ATHA) (OTCQB: AHNRF) ("Athena" or the "Company") is pleased to provide an exploration update from its Excelsior Springs Project ("Excelsior" or the "Project") in Nevada. Mammoth Minerals Limited (ASX: M79) ("Mammoth") has been aggressively exploring Excelsior pursuant to its option agreement to earn an 80% interest in the Project over five years, providing Athena a free-carry to Definitive Feasibility Study thereafter (see Company press releases dated June 2, 2025, and August 22, 2025).
Athena Provides Updates Across Gold Portfolio
2026-06-09 07:00:00
White Rock, British Columbia--(Newsfile Corp. - June 9, 2026) - Athena Gold Corporation (CSE: ATHA) (OTCQB: AHNRF) ("Athena" or the "Company") is pleased to provide an update across its portfolio of gold projects in Ontario, Canada, including Laird Lake, Forester, Oneman Lake, and Nevada, USA, namely Excelsior Springs. Drilling remains ongoing at Athena's Laird Lake project, located in the Red Lake Gold District, in proximity to West Red Lake Gold's Madsen Mine and Kinross Gold's Great Bear Project.
2026-05-26 07:00:00
White Rock, British Columbia--(Newsfile Corp. - May 26, 2026) - Athena Gold Corporation (CSE: ATHA) (OTCQB: AHNRF) ("Athena" or the "Company") is pleased to provide an exploration update from its ongoing maiden drill campaign at its flagship Laird Lake project in Ontario's Red Lake Gold District. Included in today's results are visual observations from Holes LL-26-004 and LL-26-005, the latter of which intersected a zone containing visible gold ("VG").
Athena Reports Further Encouraging Visual Results from Holes 2 and 3 at Laird Lake
2026-05-15 07:00:00
White Rock, British Columbia--(Newsfile Corp. - May 15, 2026) - Athena Gold Corporation (CSE: ATHA) (OTCQB: AHNRF) ("Athena" or the "Company") is pleased to provide an exploration update from its ongoing maiden drill campaign at its flagship Laird Lake project in Ontario's Red Lake Gold District. The Company is currently awaiting on assays from Hole LL-26-001 which intersected a broad zone of sulfidized banded iron formation (see Company press release dated April 21, 2026), which is expected in the coming weeks.
Frequently Asked Questions
What is the current Athira Pharma, Inc. (ATHA) stock price?
Athira Pharma, Inc.(NASDAQ:ATHA) stock price is $6.75 in the last trading session. During the trading session, ATHA stock reached the peak price of $8.36 while $2.1955 was the lowest point it dropped to. The percentage change in ATHA stock occurred in the recent session was --6.12% while the dollar amount for the price change in ATHA stock was -$-0.44.
ATHA's industry and sector of operation?
The NASDAQ listed ATHA is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of ATHA?
Mark F. Worthington
| General Counsel, Chief Compliance Officer & Corporate Secretary
Kevin Church
| Chief Scientific Officer
Robert Renninger
| Chief Financial Officer
Julie Rathbun
| Head of Investor Relations
Mark J. Litton
| President, Chief Executive Officer & Director
How many employees does ATHA have?
Number of ATHA employees currently stands at 26. ATHA operates from 18706 North Creek Parkway, Bothell, WA 98011, US.
Link for ATHA official website?
Official Website of ATHA is: https://www.athira.com
How do I contact ATHA?
ATHA could be contacted at phone #425 620 8501 and can also be accessed through its website. ATHA operates from 18706 North Creek Parkway, Bothell, WA 98011, US.
How many shares of ATHA are traded daily?
The average number of ATHA shares traded daily for last 3 months was 1.06M.
What is the market cap of ATHA currently?
The market value of ATHA currently stands at $26.62M with its latest stock price at $6.75